ACTA MEDICINAE 2/2012 ONKOLOGIE
Transkript
ACTA MEDICINAE 2/2012 ONKOLOGIE
ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 2 Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska 2 Chemoterapie a hormonální léčba karcinomu prsu 3 Prevence nevolnosti a zvracení po chemoterapii 4 Novinky v léčbě karcinomu prsu 5 Projekt 35 – příliš mladá na karcinom prsu? 5 Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu 5 Biologická léčba nádorů ledvin 6 Karcinom plic 7 Komplexní léčba metastatického kolorektálního karcinomu 7 Karcinom žaludku 7 Germinální nádory varlat – přehled diagnostiky a terapie 8 Současné možnosti léčby karcinomu slinivky břišní 9 Výživa onkologického pacienta 9 Současné možnosti léčby průlomové bolesti onkologických pacientů 10 Léčba olanzapinem u pacientů se schizofrenií 10 Depresivní porucha a její léčba 11 Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě kolektiv autorů MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska kolektiv autorů 1 Prorok, P. – Kramer, B. – Gohagan, J.: Screening Theory and Study Design: The Basics. In: Kramer, B. – Gohagan, J. – Prorok, P. (eds.): Cancer Screening – Theory and Practise. New York, Marcel Dekker, 1999. 2 Rada Evropské unie: Doporučení rady ze dne 2. prosince 2003 o screeningu zhoubných nádorů. On-line ec.europa.eu/health/ph_information/ dissemination/diseases/docs/cancer_recommendation_cs.pdf, cit. 20. 8. 2008. 3 Arbyn, M. – Anttila, A. – Jordan, J. – Ronco, G. – Schenck, U. – Segnan N., et al.: European guidelines for quality assurance in cervical can cer screening, 2nd ed. Luxembourg, European Communities, 2008. 4 Perry, N. – Broeders, M. – de Wolf, C. – Tornberg, S. – Holland, R. – von Karsa, L., et al. (eds.): European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. Luxembourg, Office for Official Publications of the EC, 2006. 5 Segnan, N. – Patnick, J. – von Karsa, L. (eds.): European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg, Publications Office of the European Union, 2010. 6 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. On-line http://www.svod.cz. 2007, cit. 2009. 7 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. 2005, www.svod.cz, cit. 14. 9. 2009. 8 Pavlík, T. – Dušek, L. – Májek, O. – Žaloudík, J.: Five-Year Survival Rates of Cancer Patients in the Czech Republic. In: Dušek, L., et al. (eds.): Czech Cancer Care in Numbers 2008–2009. Praha, Grada Publi shing, 2009. 9 Pavlik, T. – Majek, O. – Muzik, J. – Koptikova, J. – Slavicek, L. – Finek, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health, 2012, 12 (1), s. 117. 10Nystrom, L. – Andersson, I. – Bjurstam, N. – Frisell, J. – Nordenskjold, B. – Rutqvist, L. E.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 2002, 359 (9310), s. 909–919. 11Mandel, J. S. – Bond, J. H. – Church, T. R. – Snover, D. C. – Bradley, G. M. – Schuman, L. M., et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 1993, 328 (19), s. 1365–1371. 12Hakama, M. – Rasanen-Virtanen, U.: Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiol. 1976, 103 (5), s. 512–517. 13Day, N. – Williams, D. – Khaw, K.: Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer, 1989, s. 954–958. 14Lieberman, D. – Nadel, M. – Smith, R. A. – Atkin, W. – Duggirala, S. B. – Fletcher, R., et al.: Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc, 2007, 65 (6), s. 757–766. 15Vainio, H. – Bianchini, F. (eds.): Breast Cancer Screening. Lyon, IARCPress, 2002. 16Althuis, M. D. – Dozier, J. M. – Anderson, W. F. – Devesa, S. S. – Brinton, L. A.: Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol, 2005, 34 (2), s. 405–412. 17Brenner, H. – Gondos, A. – Arndt, V.: Recent major progress in longterm cancer patient survival disclosed by modeled period analysis. J Clin Oncol, 2007, 25 (22), s. 3274–3280. 18de Vries, E. – Karim-Kos, H. E. – Janssen-Heijnen, M. L. – Soerjomataram, I. – Kiemeney, L. A. – Coebergh, J. W.: Explanations for worsening cancer survival. Nat Rev Clin Oncol, 2010, 7 (1), s. 60–63. 19Karsa, L. – Anttila, A. – Ronco, G. – Ponti, A. – Malila, N. – Arbyn, M., et al.: Cancer Screening in the European Union: Report on the implementa tion of the Council Recommendation on cancer screening. Luxembourg, European Communities, 2008. 20Zavoral, M. – Suchanek, S. – Zavada, F. – Dusek, L. – Muzik, J. – Sei fert, B., et al.: Colorectal cancer screening in Europe. World J Gastro enterol, 2009, 15 (47), s. 5907–5915. 21Majek, O. – Danes, J. – Skovajsova, M. – Bartonkova, H. – Buresova, L. – Klimes, D., et al.: Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health, 2011, 11, s. 288. 22Mansmann, U. – Crispin, A. – Henschel, V. – Adrion, C. – Augustin, V. – Birkner, B., et al.: Epidemiology and quality control of 245 000 outpatient colonoscopies. Dtsch Arztebl Int, 2008, 105 (24), s. 434–440. 23Kaminski, M. F. – Regula, J. – Kraszewska, E. – Polkowski, M. – Wojciechowska, U. – Didkowska, J., et al.: Quality indicators for colo noscopy and the risk of interval cancer. N Engl J Med, 2010, 362 (19), s. 1795–1803. Chemoterapie a hormonální léčba karcinomu prsu MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno 1 Kaufmann, M. – von Minckwitz, G. – Bear, H. D., et al.: Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18 (12), s. 1927–1934. 2 Ring, A. E. – Smith, I. E. – Ashley, S., et al.: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer, 2004, 91, s. 2012–2017. 3 Goldhirsch, A. – Wood, W. C. – Gelber, R. D., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22 (8), s. 1736–1747. 4 Fischer, B. – Neony, J. H. – Bryant, J., et al.: Treatment of lymphnode-negative, oestrogen receptor positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, 2004, 364, s. 858–868. 5 Albain, K. – Barlow, W. – O´Malley, F., et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on phase III intergroup trial 0100 (SWOG.-8814). Breast Cancer Res Treat, 2004, 88 (dopl. 1), abs. 37. 6 Henderson, I. C. – Berry, D. A. – Demetri, G. D., et al.: Improved ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura outcomes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regiment for patiens with node positive primary breast cancer. J Clin Oncol, 2003, 21, s. 976–983. 7 Roche, H. – Fumoleau, P. – Spielman, M., et al.: Sequential adjutant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:the FNCLCC PACS 01 Trial. J Clin Oncol, 2006, 24 (36), s. 5664–5671. 8 Francis, P. – Crown, J. – Di Leo, A., et al.: BIG 02-98 Collaborative Group. Adjutant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst, 2008, 100 (2), s. 121–133. 9 Martin, M. – Pienkowski, T. – Mackey, J., et al.: Breast Cancer International Researche Group 001 Investigators. Adjutant docetaxel for node-positive breast cancer. N Engl J Med, 2005, 352 (22), s. 2302–2313. 10Jones, et al.: Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S5, abs. 12. 11Cuzik, J. – Ambroisine, L. – Davidson, N., et al.: Use of luteinising-hor mone-realising hormone agonists as adjuvant treatment in preme nopausal patiens with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet, 2007, 369, s. 1711–1723. 12Peto, R. – Davies, C., and the ATLAS investigators: ATLAS (Adjutant Tamoxifen Longer Against Shorter):international randomised trial of 10 vs 5 years of adjutant tamoxifen among 11,500 women: prelimina ry results. Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S00, abs. 48. 13Rea, D. W. – Hanley, K. – Marshall, M., et al.: aTTom (adjutant Tamoxi fen-To offer more?): Randomised trial of 10 versus 5 years of adjutant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer- Preliminary results. Proc Am Soc Clin Oncol, 2 008, abs. 513. 14Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 2008, 9, s. 45–53. 15Coates, A. S. – Kashaviah, A. – Thurlimann, B., et al.: Five years of le trozole compared with tamoxifen as initial adjutant therapy for post menopausal women with endocrine-responsive early breast cencer: update of study BIG 1-98. J Clin Oncol, 207, 25, s. 486–492. 16Goss, P. E. – Unyle, J. N. – Martino, S., et al.: Randomized trial of letrozole following tamoxifen as extended adjutant therapy in receptor-positive breast cancer: update findings from NIC CTG MA17. J Natl Cancer Indy, 2005, 97, s. 1262–1271. 17Carrick, S. – Parker, S. – Wilcken, N., et al.: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Databáze Syst Rev, 2005, 2, Art No. CD003372, doi: 10.1002/14651858. 18Bruzzi, P. – Del Mastro, L. – Formani, M. P., et al.: Objective response to chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patiens. J Clin Oncol, 2005, 23, s. 5117–5125. 19Greenberg, P. A. – Hortobagyi, G. N. – Smith, T. L., et al.: Long-term follow-up of patiens with complete remission following combina tion chemotherapy for metastatic breast cancer. J Clin Oncol, 1996, 14, s. 2197–2205. 20Nabholtz, J. M. – Falkon, C. – Campos, D., et al.: Docetaxel and do xorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a rando mized, multicenter, phase III. trial. J Clin Oncol, 2003, 21, s. 968–975. 21Jassem, J. – Pienkowski, T. – Pluzanska, A., et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer:final re sults of a randomised phase III multicenter trial. J Clin Oncol, 2001, 19, s. 1707–1715. 22Boneneterre, J. – Thurlimann, B. – Robertson, J. F., et al.: Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 200, 18, s. 3748–3757. 23Nabholtz, J. M. – Buzdar, A. – Pollak, M., et al.: Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postme nopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 2000, 18, s. 3758–3767. 24Howell, A. – Robertson, J. F. – Abram, P., et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol, 2004, 22, s. 1605–1613. 25Klijn, J. G. – Blamey, R. W. – Boccardo, F., et al.: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol, 2001, 19, s. 343–353. Prevence nevolnosti a zvracení po chemoterapii doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Grunberg, S. – Deuson, R. R. – Mavros, P., et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Can cer, 2004, 100, s. 2261–2268. 2 Roila, F. – Herrstedt, J. – Aapro, M., et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus confe rence. Ann Oncol, 2010, 21 (dopl. 5), s. v232–v243. 3 Ettinger, D. S., and Pannel Members: NCCN Clinical Practice Guidelines in Oncology. Version I.2012. //www.nccn.org/professionals/physician_gls/ . 4 Ellebaek, E. – Herrstedt, J.: Optimizing antiemetic therapy in multipleday and multiple cycles of chemotherapy. Current Opinion in Suppor tive and Palliative Care, 2008, 2, s. 28–34. 5 Schwartzberg, L. – Szabo, S. – Gilmore, J., et al.: Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately and highly emetogenic chemotherapy (LEC, MEC, HEC). Curr Med Res Opinion, 2011, 27, s. 837–845. 6 Hesketh, P. J. – Aapro, M. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard- -of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer, 2010, 18 (9), s. 1171–1177. 7 Warr, D. G. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Sup port Care Cancer, 2011, 19 (6), s. 807–813. 8 Rojas, C. – Thomas, A. G. – Alt, J., et al.: Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. European J Pharmacol, 2010, 626, s. 193–199. 9 Navari, R. M.: Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Nation Compr Cancer Network, 2007, 5, s. 51–59. 10Warr, D. G. – Grunberg, S. M. – Gralla, R. J. – Hesketh, P. J. – Roila, F. – deWit, R., et al.: The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura trials. E ur J Cancer, 2005, 41, s. 1278–1285. 11Botrel, T. E. – Clark, O. A. – Clark, L., et al.: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care in Cancer, 2011, 19, s. 823–832. 12Rapoport, B. L. – Jordan, K. – Boice, J. A., et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with broad spectrum of moderately emetogenic chemotherapies and tumor types: a randomized, double blind study. Support Care Cancer, 2009, doi: 10.1007/s00520-009-0680-9. 13Grunberg, S. – Clark-Snow, R. A. – Koeller, J.: Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Support Care Cancer, 2010, 18 (dopl. 1), s. S1–S10. 14Bash, E. – Prestrud, A. A. – Hesketh, P. J. – Kris, M. G., et al.: Antieme tics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2011, doi: 10.1200/JCO.2010.34.4614. Novinky v léčbě karcinomu prsu MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Petruželka, L.: Současné možnosti a nové perspektivy systémové léčby karcinomu prsu. Klin Farmakol Farm, 21, 2007, s. 11–17. 2 Petruželka, L.: Karcinom prsu – jak dál v diagnostice a léčbě ve světle nových možností. Vnitř Lék, 53, 2007, s. 22–23. 3 Petruželka, L.: Nové možnosti léčby ErbB2 a hormonálně dependentních karcinomů prsu. Klin. Farmakoter, 2012, v tisku. 4 Higgins, M. J. – José Baselga, J.: Targeted therapies for breast cancer. J Clin Invest, 2011, 121 (10), s. 3797–3803. 5 Tang, R. Y. – Finn, R. S.: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. British Journal of Cancer, 2012, 106, s. 6–13. 6 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemothe rapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 2001, s. 783–790. 7 Pegram, M. D. – Konecny, G. E. – O’Callaghan, C., et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst, 2004, 96, s. 739–745. 8 Petruželka, L.: Biologická léčba karcinomu prsu. Onkologie, 3, 2009, s. 19–27. 9 Baselga, J. – Cortés, J. – Kim, S.-B., et al.: Pertuzumab plus trastuzu mab plus docetaxel for metastatic breast cancer. N Engl J Med, 2011, 366 (2), s. 109–119. 10Lewis Phillips, G. D. – Li, G. – Dugger, D. L., et al.: Targeting HER2-po sitive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res, 2008, 68, s. 9280–9290. 11Beeram, M. – Burris, H. A. – Modi, S. – Birkner, M. – Girish, S. – Tibbitts, J.: A phase I study of trastuzumab-DM1 (T-DM1), a fi rst in class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). Proc Am Soc Clin Oncol, 2008, 26, abstr. 1028. 12Krop, I. E. – Mita, M. – Burris, H. A., et al.: A phase I study of weekly dosing of trastuzumab- DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Prezentováno: 31st Annual San Antonio Breast Cancer Symposium; 10.–14. 12. 2008; San Antonio, TX. Abstrakt 3136. 13Vogel, C. L. – Burris, H. A. – Limentani, S., et al.: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol, 2009, 27 (dopl. 15), abstr. 1017. 14Alvarez, R. H. – Valero, V. – Gabriel, N. – Hortobagyi, G. N.: Emerging Targeted Therapies for Breast Cancer. J Clin Oncol, 2010, 28, s. 3366–3379. 15Jordan, M. A. – Kamath, K. – Manna, T., et al.: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther, 2005, 4, s. 1086–1095. 16Okouneva, T. – Azarenko, O. – Wilson, L., et al.: Inhibition of centromere dynam-ics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008, 7, s. 2003–2011. 17Towle, M. J. – Salvato, K. A. – Budrow, J., et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res, 2001, 61, s. 1013–1021. 18Goel, S. – Mita, A. C. – Mita, M., et al.: A Phase I study of eribulin mesy late (E7389), a mechanistically novel inhibitor of microtubule dyna mics, in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4207–4212. 19Tan, A. R. – Rubin, E. H. – Walton, D. C., et al.: Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4213–4218. 20Vahdat, L. T. – Pruitt, B. – Fabian, C. J., et al.: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2009, 27, s. 2954–2961. 21Cortes, J. – Vahdat, L. – Blum, J. L., et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol, 2010, 28, s. 3922–3928. 22Iwata, H. – Aogi, K. – Masuda, N., et al.: Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol, 2010, 28, s. 1081. 23Twelves, C. – Loesch, D. – Blum, J. L., et al.: A phase III study(EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously trea ted with an anthracycline and a taxane. J Clin Oncol, 2010, 28, abstr. CRA1004. 24Cigler, T. – Vyndat, L.: Eribulin mesylate for the treatment of breast cancer. Expert Opin. Pharmacother, 2010, 11 (9), s. 1587–1593. 25Cortes, J. – O’Shaughnessy, J. – Losech, D., et al.: Eribulin monothe rapy versus treatment of physician’s choice in patients with metasta tic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 2011, 377, s. 914–923. 26Hortobagyi, G. N.: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2011 San Antonio Breast Cancer Symposium. Updated late breaking abstract No. S3-7, 7. 12. 2011. 27Dawood, S. – Broglio, K. – Giordano, S. H., et al.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 2010, 28 (1), s. 92–98. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura Projekt 35 – příliš mladá na karcinom prsu? doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Parkin, D. M.: Cancers attributable to exposure to hormones in the UK in 2010. Br J Cancer, 2011, 105 (S2), s. S42–S48. 2 Sidoni, A. – Cavaliere, A. – Bellezza, G. – Scheibel, M. – Bucciarelli, E.: Breast cancer in young women: :clinicopathological features and biological specificity. Breast, 2003, 12 (4), s. 247–250. 3 Ménard, S. – Casalini, P. – Cascinelli, N. – Balsari, A.: Breast carcinoma in young patients. Lancet, 2000, 356 (9235), s. 1113, 1123. 4 Jmor, S. – Al-Sayer, H. – Heys, S. D. – Payne, S. – Miller, I. – Ah-See, A. – Hutcheon, A. – Eremin, O.: Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb, 2002, 47 (5), s. 693–699. 5 Hartmann, S. – Reimer, T. – Gerber, B.: Management of early invasive breast cancer in very young women (<35 years). Clin Breast Cancer, 2011, 11 (4), s. 196–203. 6 Francis, P. A.: Optimal adjuvant therapy for very young breast cancer patients. Breast, 2011, 20 (4), s. 297–302. 7 de Bree, E. – Makrigiannakis, A. – Askoxylakis, J. – Melissas, J. – Tsiftsis, D. D.: Pregnancy after breast cancer. A comprehensive review. J Surg Oncol, 2010, 101 (6), s. 534–542. 8 Hulvat, M. C. – Jeruss, J. S.: Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol, 2009, 10 (5–6), s. 308–317. Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha 1 Chen, C. J. – Liang, K. Y. – Chang A. S., et al.: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology, 1991, 13, s. 398–406. 2 Fattovich, G. – Ribero, M. L. – Pantalena, M., et al.: Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat, 2001, 8, s. 206–216. 3 Wilhelm, S. – Carter, C. – Lynch, M., et al.: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 2006, 5, s. 835–844. 4 Llovet, J. M. – Bruix, J.: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 (dopl. 1): s. S20–S37. 5 Llovet, J. M. – Bruix, J.: Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48, s. 1312–1327. 6 Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo controlled trial. Lancet Oncol, 2009, 10, s. 25–34. 7 Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby onkologických onemocnění 2011. Dostupné z http://www.linkos.cz/ informace-pro-praxi/zasady-cytostaticke-lecby/ [cit. 4. 5. 2012]. 8 Yoon, S. K. – Ye, S. L. – Marrero, J., et al.: GIDEON (Global Investigation of therapeutic DEcision in Hepatocellular Carcinoma and Of its treatment with sorafeNib) interim results: regional subgroup analysis. Hepatol Int, 2011, 5, 3–558, FC02–05. 9 Abrahámová, J.: Postavení sorafenibu v současné medikamentózní léčbě hepatocelulárního karcinomu. In: Farmakoterapie – Léčba hepa tocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 32–39. 10Kupec, M. – Büchler, T. – Abrahámová, J.: Dlouhodobé přežití pacienta s pokročilým hepatocelulárním karcinomem léčeného sorafenibem. In: Farmakoterapie – Léčba hepatocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 40–41. 11American Society of Clinical Oncology 2012 Gastrointestinal Cancers Sym posium, 19.–21. leden 2012, San Francisco, Kalifornie. Biologická léčba nádorů ledvin doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň 1 Escudier, B. – Pluzanska, A. – Koralewski, P., et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. AVOREN Trial investigators. Lancet, 2007,370 (9605), s. 2103–2111. 2 Rini, B. I. – Halabi, S. – Rosenberg, J. E., et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: fi nal results of CALGB 90206. J Clin Oncol, 2010, 28 (13), s. 2137–2143. 3 Motzer, R. J. – Michaelson, M. D. – Redman, B. G., et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 (1), s. 16–24. 4 Motzer, R. J. – Rini, B. I. – Bukowski, R. M., et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295 (21), s. 2516–2524. 5 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 (2), s. 115–124. 6 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (22), s. 3584–3590. 7 Hudes, G. – Carducci, M. – Tomczak, P., et al.: Temsirolimus, interfe ron alfa, or both for advanced renal-cell carcinoma. Global ARCC Trial. N Engl J Med, 2007, 356 (22), s. 2271–2281. 8 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010, 28 (6), s. 1061–1068, e-pub 25. 1. 2010. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 9 Escudier, B.. – Eisen, T. – Stadler, W. M., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med, 2007, s. 356 (2), s. 125–134. 10Escudier, B. – Szczylik, C. – Hutson, T. E.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (8), s. 1280–1289, e-pub 26. 1. 2009. Erratum in: J Clin Oncol, 2009, 27 (13), s. 2305. 11Stadler, W. M. – Figlin, R. A. – McDermott, D. F., et al.: ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 2010, 116 (5), s. 1272–1280. 12Beck, J. – Bajetta, E. – Escudier, B., et al.: A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. European Journal of Cancer Suppl, 2007, 5, 300 s. 4506. 13Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group. Lancet, 2008, 372 (9637), s. 449–456. 14SPC Votrient, červen 2010. 15CHMP assessment report/Votrient,14. 6. 2010, www.ema.europa.eu. 16Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol, 2010, 28, s. 1061–1068. 17Sternberg, C. N. – Szczylik, C. – Lee, E., et al.: A randomized, doubleblind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presentation at the 45th Annual Meeting American Society of Clinical Oncology, Orlando, Florida, 29. 5.–2. 6. 2009. 18Hutson, T. E., et al.: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2010, 28 (3), s. 475–480. Karcinom plic MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno 1 Adam, Z., et al.: Systémové a paraneoplastické projevy maligních onemocnění. Vnitř Lék, 2007, 53 (3), s. 253–285. 2 Demedts, I. K. – Vermaelen, K. Y. – van Meerbeeck, J. P.: Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 2010, 35, s. 202–215. 3 Gao, G. – Ren, S. – Li, A. – Xu, J. – Xu, Q. – Su, C. – Guo, J. – Deng, Q. – Zhou, C.: Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-linetreatment of advanced non-small-cell lung cancer with mutated EGFR: Ameta-analysis from six phase III randomized controlled trials. Int J Cancer, 2011, doi: 10.1002/ijc.27396. 4 Goldstraw, P. – Crowley, J. – Chansky, K. – Giroux, D. J. – Groome, P. A., et al.: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2007, 2, s. 706–714. 5 Goldstraw, P. – Crowley, J. J.: The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol, 2006, 1, s. 281–286. 6 Hansen, M.: Paraneoplastic syndromes and tumor markers for small-cell and non-small-cell lung cancer. Curr Opin Oncol, 1990, 2, s. 345–351. 7 Johnson, B. E. – Janne, P. A.: Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am, 2004, 18, s. 309–322. 8 Molina, J. R. – Dusi, A. A. – Jett, J. R.: Advances in Chemotherapy of Non-small Cell Lung Cancer. CHEST, 2006, 130, s. 1211–1219. 9 Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. J Thorac Oncol, 2006, 1, s. 270–278. 10NSCLC Meta-Analyses Collaborative Group: Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small- Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol, 2008, 26, s. 4617–4625. 11Patel, S. – Macdonald, O. K. – Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009, 115, s. 842–850. 12Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002. 13Pešek, M. – Skřičková, J. – Kolek, V. – Zatloukal, P. – Petruželka, L. – Tomíšková, M. – Krákorová, G. – Grygárková, I. – Havel, P. – Zemanová, M. – Minárik, M. – Svobodník, A. – Dušek, L. – Chroust, K. – Kaisarová, P. – Šlégrová, Z. – Berkovcová, J. – Hajdúch, M.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Studia Pneumologica et Phthiseologica, 2009, 69, 2, s. 61–68. 14Pijls-Johannesma, M. – De Ruysscher, D. – Vansteenkiste, J., et al.: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev, 2007, 33, s. 461–473. 15Reck, M. – von Pawel, J. – Zatloukal P., et al.: Phase III trial of cispla tin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27 (14), s. 2415. 16Rosell, R. – Carcereny, E. – Gervais, R. – Vergnenegre, A. – Massuti, B. – Felip, E., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-posi tive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13, s. 239–246. 17Scott, W. J. – Howington, J. – Feigenberg, S., et al.: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132, s. 234S. 18Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J, 2009, 33, s. 915–930. 19Secretan, B. – Straif, K. – Baan, R., et al.: A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol, 2009, 10, s. 1033–1034. 20Shepherd, F. A. – Crowley, J. – van Houtte, P. – Postmus, P. E. – Carney, D., et al.: The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol, 2007, 2, s. 1067–1077. 21Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjuvant chemothera py following surgical resection for small-cell carcinoma of the lung. J Clin Oncol, 1988, 6, s. 832–838. 22Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl Compr Canc Netw, 2008, 6, s. 323–331. 23Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119–133. 24Skřičková, J., et al.: Bronchogenní karcinom (41–62). In: Adam, Z. – Vorlíček, J. – Vaníček, J., et al.: Diagnostické a léčebné postupy u maligních ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura chorob. Grada Publishing, Praha, 2004. 25Yu, J. B. – Decker, R. H. – Detterbeck, F. C. – Wilson, L. D.: Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 2010, 5, s. 215–219. 26Zatloukal, P. – Petruželka, L.: Karcinom plic. Praha, Grada, 2001. 27Zhou, C. – Wu, Y. L. – Chen, G. – Feng, J. – Liu, X. Q. – Wang, C., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12, s. 735–742. Komplexní léčba metastatického kolorektálního karcinomu MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno 1 Software pro vizualizaci onkologických dat (SVOD), www.svod.cz. 2 Screening kolorektálního karcinomu, www.kolorektum.cz. 3 Van Cutsen, E. – Kohne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360, s. 1408–1417. 4 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: N Engl J Med, 2004, 350, s. 2335–2342. 5 Saltz, L. B. – Clarke, S. – Díaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 2008, 26, s. 2013–2019. 6 Bismuth, H. – Adam, R. – Levi F., et al.: Resection of nonresectable liber metastase from colorectal cancer after neoadjuvant chemotherapy. Ann Surg, 1996, 224, s. 509–522. 7 Adam, R. – Wicherts, D. A. – de Haas, R. J., et al.: Patient wit initially unresectable colorectal liver metastase : is there a posibility of cure? J Clin Oncol, 2009, 27, s. 1829–1835. 8 Nordlinger, B. – Skrbte, H. – Glimelius, B., et al.: Preoperative chemotherapy whith FOLFOX4 and surgery versus surgery alone for resectab le liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet, 2008, 371, s. 1007–1016. 9 Kubala, E. – Bartoš, J. – Petrželka, L., et al.: Safety and effectivness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer in eldery population:updated results from a large Czech observational registry. ASCO GI, 2010. Karcinom žaludku MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno 1 Cunningham, D. – Allum, W. H. – Stenning, S. P., et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355, s. 11–20. 2 Macdonald, J. S. – Smalley, S. R. – Benedetti, J., et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345, s. 725–730. 3 Wagner, A. D. – Grothe, W. – Haerting, J., et al.: Chemotherapy in ad vanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006, 24, s. 2903–2909. 4 Cunningham, D. – Starling, N. – Rao, S., et al.: Capecitabine and oxa liplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358 (1), s. 36–46. 5 Van Cutsen, E. – Moiseyenko, V. M. – Tjulandin, S., et al.: Phase III stu dy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol, 2006, 24, s. 4991–4997. 6 Ajani, J. A. – Moiseyenko, V. M. – Tjulandin, S., et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroeso phageal adenocarcinoma: The V-325 Study Group. J Clin Oncol, 2007, 25, s. 3210–3216. 7 Moehler, M. – Eimermacher, A. – Siebler, J., et al.: Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer, 2005, 92, s. 2122–2128. 8 Van Cutsem, E. – Kang, Y. – Chung, H., et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol, 2009, 27 (15S), LBA4509. Germinální nádory varlat – přehled diagnostiky a terapie MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, cit. 4. 10. 2012, http://www.svod.cz. 2 McGlynn, K. A. – Cook, M. B.: Etiologic factors in testicular germ-cell tumors. Future Oncol, 2009, 5 (9), s. 1389–1402. 3 International Germ Cell Cancer Collaborative Group: Internatio nal Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol, 1997, 15, s. 594–603. 4 Capelouto, C. C. – Clark, P. E. – Ransil, B. J., et al.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol, 1995, 153, s. 981–985. 5 Abrahámová J.: Léčebné postupy u nepokročilých testikulárních ger minálních nádorů neseminomového typu. Klinická onkologie, 2008, 21, ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 3, s. 81–85. 6 Abrahámová J.: Radioterapie germinálních nádorů. In: Abrahámová, J. – Dušek, L. – Povýšil, C., et al.: Nádory varlat, Grada, 2008, s. 195–205. 7 Krege, S. – Beyer, J. – Souchon. R. – et al.: European consensus confe rence on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol, 2008, 53 (3), s. 497–513. 8 Kondagunta, G. V. – Bacik, J. – Donadio, A., et al.: Combination of pa clitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 2005, 23 (27), s. 6549–6555. 9 Einhorn, L. H. – Williams, S. D. – Chamness, A., et al.: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 2007, 357 (4), s. 340–348. 10Fossa, S. D. – Bokemeyer, C. – Gerl, A., et al.: Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 1999, 85, s. 988–997. 11Buchler, T. – Kubankova, P. – Boublikova, L., et al.: Detection of se cond malignancies during long-term follow-up of testicular cancer survivors. Cancer, 2011, 117, s. 4212–4218. Současné možnosti léčby karcinomu slinivky břišní MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Hidalgo, M.: Pancreatic Cancer. N Engl J Med, 2010, 362, s. 1605–1617. 2 Verdecchia, A. – Francisci, S. – Kunkler, I., et al.: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncology, 2007, 8 (9), s. 784–796. 3 Roazzi, P. – Capocaccia, R. – Santaquilani, M. – Carrani, E.: Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol, 2003, 14 (dopl. 5), s. 150–155. 4 www.svod.cz. 5 Dušek, L., et al.: Czech Cancer Care in Numbers 2008–2009. Grada Publishing, Praha, 2009. 6 Hanash, S. M., et al.: Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol, 2011, 8, s. 142–150. 7 Abramson, M. A. – Jazag, A. – van der Zee, J. A. – Whang, E. E.: The Molecular Biology of Pancreatic Cancer. Gastrointest Cancer Res, 2007, 1, s. 7–12. 8 Cascinu, S. – Falconi, M. – Valentini, V. – Jelic, S.: On behalf of the ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, s. 55–58. 9 Chang, D. K. – Johns, A. L., et al.: Margin Clearance and Outcome in Resected Pancreatic Cancer. J Clin Oncol, 2010, 27, s. 2855–2862. 10Balcom, J. H. – Rattner, D. W. – Warshaw, A. L. – Chang, Y. – Fernandez-del, C. C.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg, 2001, 136, s. 391–398. 11Birkmeyer, J. D. – Finlayson, S. R. – Tosteson, A. N. – Sharp, S. M. – Warshaw, A. L. – Fisher, E. S.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery, 1999, 125, s. 250–256. 12Stocken, D. D. – Buchler, M. W. – Dervenis, C. – Bassi, C. – Jeekel, H. – Klinkenbijl, J. H., et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005, 92, s. 1372–1381. 13GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer, 1987, 59, s. 2006–2010. 14Klinkenbijl, J. H. – Jeekel, J. – Sahmoud, T. – van Pel, R. – Couvreur, M. L. – Veenhof, C. H., et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer coope rative group. Ann Surg, 1999, 230, s. 776–782. 15Neoptolemos, J. P. – Dunn, J. A. – Stocken, D. D. – Almond, J. – Link, K. – Beger, H., et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 2001, 358, s. 1576–1585. 16Regine, W. F. – Winter, K. W. – Abrams, R. – Safran, H. – Hoffman, J. P. – Konski, A., et al.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol, 2006, 24, No. 18S: 4007. 17Ben-Josef, E. – Lawrence, T. S.: The importance of local kontrol in pancreatic cancer. Clin Oncol, 2012, 9, s. 9–10. 18Stathis, A. – Moore, M. J.: Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol, 7, 2010, s. 163–172. 19Huguet, F. – Girard, N. – Guerche, C. S. – Hennequin, C. – Mornex, F. – Azria, D.: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol, 2009, 27, s. 2269–2277. 20Heinemann, V. – Boeck, S. – Hinke, A. – Labianca, R. – Louvet, C.: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, s. 82–85. 21Conroy, T., et al.: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Eng J Med, 2011, 364, s. 1817–1825. 22Tempero, M. A., et al.: Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol, 2011, s. 93–99. 23Philip, P., et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or meta static pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol, 2007, 25, s. a4509. 24Van Cutsem, E. – Vervenne, W. – Bennouna, J., et al.: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreaticcancer. J Clin Oncol, 2008, 27, s. 2231–2237. 25Kindler, H. L. – Priberg, G. – Singh, D. A., et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2005, 23, s. 8033–8040. 26Van Cutsem, E. – van de Velde, H. – Karasek, P., et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004, 22, s. 1430–1438. 27Moore, M. J., et al.: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25, s. 1960–1966. 28Pelzer, U. – Stieler, J., et al.: A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer- CONKO 003. J Clin Onco, 2007, 25 (dopl.), s. 201. 29Harsha, H. C. – Kandasamy, K. – Ranganathan, P., et al.: A compendium of potential biomarkers of pancreatic cancer. PLoS Med, 2009, 6 (4), s. e1000046. 30Burris, H. A., et al.: J Clin Oncol, 1997, 15, s. 2403–2413. 31Conroy, T., et al.: ASCO, 2010, abstrakt 4010. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura Výživa onkologického pacienta doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Andreyev, H. J. N. – Norman, A. R. – Oates, J. – Cunningham, D.: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 1998, 34, s. 503–509. 2 Awad, S. – Tan, B. J. – Cui, H., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutrition, 2012, 31, s. 74–77. 3 Barber, M. D. – Ross, J. A. – Fearon, K. C. H.: Cancer cachexia. Surg Oncol, 1999, 8, s. 133–141. 4 Braga, M. – Gianotti, L. – Radaelli, G., et al.: Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized doube-blind phase 3 trial. Arch Surg, 1999, 134 (4), s. 428–433. 5 Camps, C. – Iranzo, V. – Bremnes, R. M. – Sirera, R.: Anorexia-cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Supp Care Cancer, 2006, 14, s. 1173–1183. 6 Davidson, W. – Ash, S. – Capra, S., et al.: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutrition, 2004, 23, s. 239–247. 7 Fearon, K. C. H. – Barber, M. D. – Moses, A. G., et al.: Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol, 2006, 24, s. 3401–3407. 8 Hoda, D. – Jatoi, A. – Burnes, J., et al.: Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A singles institution´s 20-years experience. Cancer, 2005, 103, s. 863–868. 9 Khalid, U. – Spiro, A. – Baldwin, C., et al.: Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Sup por Care Cancer, 2007, 15, s. 39–46. 10McMillan, D. C. – Watson, W. S. – Preston, T. – McArdle, C. S.: Lean body mass changes in cancer patients with weight loss. Clinical Nutri tion, 2000, 19, s. 403–406. 11Moses, A. W. G. – Slater, C. – Preston, T., et al.: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer, 2004, 90, s. 996–1002. 12Nitenberg, G. – Raynard, B.: Nutritional support of the cancer patient: issues and dilemmas. Critical Review in Oncology/Hematology, 2000, 34, s. 137–168. 13Ovesen, L. – Allingstrup, L. – Hannibal, J. – Mortensen, E. L. – Hansen, O. P.: Effect of dietary counselling on food intake, body weight, res ponse rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol, 1993, 11, s. 2043–2049. 14Ravasco, P. – Monteiro-Grillo, I. – Vidal, P. M., et al.: Dietary counselling improves patient outcomes: a prospective, randomized controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin On cology, 2005, 23, s. 1431–1438. 15Tisdale, M. J.: Cachexia in cancer patients. Nature Reviews, 2002, 2, s. 862–871. 16Zadák, Z.: Enterální výživa u pacientů s nádorovým onemocněním. In: Wilhelm, Z., et al.: Výživa v onkologii. Institut pro další vzdělávání pracovníků ve zdravotnictví, Brno, 2001. Současné možnosti léčby průlomové bolesti onkologických pacientů MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno 1 Davies, A. M. – Dickman, A. – Reid, C., et al.: The management of cancer-related breakthrough pain: Recommendations of a taskgroup of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain, 2009, 13, s. 331–338. 2 Haugen, D. F. – Hjermstad, M. J. – Hagen, N., et al.: Assessment and classification of cancer breakthrough pain: A systematic literature review. Pain, 2010, 149, s. 476–482. 3 Kabelka, L. – Lejčko, J. – Kozák, J. – Sláma, O.: Doporučený postup pro léčbu průlomové nádorové bolesti. Farmakoterapie, 2011, 7 (5), s. 521–523. 4 Portenoy, R. K. – Forbes, K. – Lussier, D. – Hanks, G.: Difficult pain problems: an integrated approach. In: Doyle, D. – Hanks, G. – Cherny, N. – Calman, K. (eds.): Oxford textbook of palliative medicine. Oxford, Oxford University Press, 2004, s. 438–458. 5 Sláma, O. – Lejčko, J. – Kozák, J., et al.: Epidemiologie a léčba průlo mové bolesti u onkologických pacientů v ČR. Výsledky výzkumného projektu PARMA. Část 1. Prevalence a klinické charakteristiky průlomo vé bolesti. Bolest, 2011, 14 (1), s. 158–160. 6 Mercadante, S. – Villari, P. – Ferrera, P. – Casuccio, A.: Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Sympt Manage, 2004, 28, s. 505–510. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura Léčba olanzapinem u pacientů se schizofrenií doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 Breier, A. – Meehan, K. – Birkett, M., et al.: A double-blind, placebocontrolled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry, 2002, 59, s. 441–448. 2 Hill, A. L. – Sun, B. – Karagianis, J. L., et al.: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry, 2011, 15, s. 11–28. 3 Kane, J. M. – Detke, H. C. – Naber, D., et al.: Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry, 2010, 167, s. 181–189. 4 Komossa, K. – Rummel-Kluge, C. – Hunger, H., et al.: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, 2010, 3, CD006654. 5 Lauriello, J. – Lambert, T. – Andersen, S., et al.: An 8-week, double blind, randomized, placebo-controlled study of olanzapine long-actinginjection in acutely ill patients with schizophrenia. J Clin Psy chiatry, 2008, 69, s. 790–799. 6 Leucht, S. – Komossa, K. – Rummel-Kluge, C., et al.: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry, 2009, 166, s. 152–163. 7 Lieberman, J. A. – Stroup, T. S. – McEvoy, J. P., et al.: Effectiveness of antipsychotic drugs in patiens with chronic schizophrenia. N Engl J Med, 2005, 353, s. 1209–1223. 8 Meehan, K. – Zhang, F. – David, S. – Tohen, M., et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol, 2001, 21, s. 389–397. 9 Meehan, K. M. – Wang, H. – David, S. R. – Nisivoccia, J. R., et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 2002, 26, s. 494–504. 10Wright, P. – Birkett, M. – David, S. R., et al.: Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry, 2001, 158, s. 1149–1151. Depresivní porucha a její léčba prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psy chiatry, 2000, 157 (dopl.), s. 1–45. 2 Bauer, M. – Bschor, T. – Kuntz, D. – Berhöfer, A. – Stöhle, A. – Müller-Oerlinghausen, B.: Double blind, placebo controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry, 2000, 157, s. 1429–1435. 3 Beck, A. T. – Rush, A. J. – Shaw, B. F. – Emery, G.: Cognitive Therapy of Depression. New York, Guilford, 1979. 4 Clinical Guidelines for The Treatment of Depressive Disorders (Clinical Practice Guidelines). The Canadian Journal of Psychiatry, 2001, 46 (dopl. 1), s. 91. 5 Crismon, M. L. – Trivedi, M. – Pigott, T. A. – Rush, A. J. – Hirschfeld, R. M. – Kahn, D. A. – De Battista, C. – Nelson, J. C. – Nierenberg, A. A. – Sackeim, H. A. – Thase, M. E.: The Texas Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry, 1999, 60, s. 142–156. 6 El-khalili, N. – Joyce, M. – Atkinson, S.: Adjunctive extended-release quetiapine fumarate in patients with major depressive disorder and ina dequate antidepressant response. 16st Annual Meeting of the American Psychiatrie Association, Washington DC, USA, 2008. 7 Frank, E. – Prien, R. F. – Jarrett, R. B. – Keller, M. B. – Kupfer, D. J. – Lavori, P. W. – Rush, A. J. – Weissmann, M. M.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry, 1991, 48, s. 851–855. 8 Geddes, J. R. – McCarney, S. M. – Davies, C. – Furukawa, T. A. – Kupfer, D. J. – Goodwin, G. M.: Relapse prevention with antidepressant drug treatment in depressive disorder: a systematic review. Lancet, 2003, 361, s. 653–661. 9 Kessler, R. C. – Berglund, P. – Demler, O., et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, s. 3095–3105. 10McPherson, S. – Cairns, P. – Carlyle, J. – Shapiro, D. A. – Richardson, P. – Taylor, D.: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand, 2005, 111 (5), s. 331–340. 11Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Popisy klinických příznaků a diagnostická vodítka (přeloženo z anglického originálu). Praha, Psychiatrické centrum, 1992, Zprávy č. 102. 12Montgomery, S. – Cutler, A. – Lazarus, E.: Extended release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. 16th European Congress of Psychiatry, Nice, Francie, 2008. 13Moore, R. G. – Garland, A.: Cognitive Therapy for Chronic and Persistent Depression. Chichester, John Wiley and Sons, 2003. 14Murray, C. J. – Lopez, A. D.: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997, 349, s. 1498–1504. 15Praško, J.: Bright light therapy. Neuroendocrinology Letters, 2008, 29 (dopl. 1), s. 33–64. 16Quitkin, F. M. – McGrath, J. P. – Stewart, J. W.: Chronological milestones to guide drug change: when should clinician switch antidepressant? Arch Gen Psychiatry, 1996, 53, s. 785–792. 17Rush, A. J. – Trivedi, M. H. – Wisniewski, S. R. – Nierenberg, A. A. – Stewart, J. W. – Warden, D., et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 2006, 163 (11), s. 1905–1917. 18Segal, Z. – Williams, J. M. – Teasdale, J.: Mindfulness -based cognitive therapy for depression. New York, The Guilford Press, 2002. 19Thase, M. E. – Friedman, E. S. – Howland, R. H.: Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psy chiatry, 2001, 62 (dopl. 18), s. 18–24. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 20Thase, M. E.: Effects of venlafaxine on blood pressure: a metanalysis of original data from 3744 depressed patients. J Clin Psychiatry, 1998, 59, s. 502–508. 21Thase, M. E.: Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. J Clin Psychiatry, 1990, 5 (dopl.), s. 51–57. 22Weisler, R. – Joyce, M. – Mc Gill, L.: Extended release quetiapine fumu rate monotherapy for major depressive disorder (MDD): a double-blind placebo-controlled study. American Psychiatric Association, Washington D. C., USA, 2008. 23Weissman, M. M. – Leaf, P. J. – Tischler, G. L., et al.: Affective disorders in five United States communities. Psychol Med, 1988, 18, s. 141–153. 24WHO: WHO Report 2001: Mental Health. New Hope: New Understanding. 2001, kapitola 2: Burden of Mental and Behavioral Disorders. 25World Health Organization, Mental Health Collaborating Centers, 1989. Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha 1 Lujambio, A. – Lowe, S. W.: The microcosmos of cancer. Nature, 2012, 484, s. 347–355. 2 Calin, G. A. – Dumitru, C. D. – Shimizu, M. – Bichi, R. – Zupo, S. – Noch, E. – Adler, H. – Rattan, S. – Keating, M. – Rai, K. – Rassenti, L. – Kipps, T. – Negrini, M. – Bullrich, F. – Croce, C. M.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 2002, 99, s. 15524–15529. 3 Lu, J. – Getz, G. – Miska, E. A. – Alvarez-Saavedra, E. – Lamb, J. – Peck, D. – Sweet-Cordero, A. – Ebert, R. L. – Mak, R. H. – Ferrando, A. A. – Downing, J. R. – Jacks, T. – Horvitz, H. R. – Golub, T. R.: MicroRNA expression profiles classify human cancers. Nature, 2005, 435, s. 834–838. 4 Yanaihara, N. – Caplen, N. – Bowman, E. – Seike, M. – Kumamoto, K. – Yi, M. – Stephens, R. M. – Okamoto, A. – Yokota, J. – Tanaka, T. – Calin, G. A. – Liu, C.-G. – Croce, C. M. – Harris, C. C.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9, s. 189–198. 5 Mitchell, P. S. – Parkin, R. K. – Kroh, E. M. – Fritz, B. R. – Wyman, S. K. – Pogosova-Agadjanyan, E. L. – Peterson, A. – Noteboom, J. – O‘Briant, K. C. – Allen, A. – Lin, D. W. – Urban, N. – Drescher, C. W. – Knudsen, B. S. – Stirewalt, D. L. – Gentleman, R. – Vessella, R. L. – Nelson, P. S. – Martin, D. B. – Tewari, M.: Circulating microRNAs as stable bloodbased markers for cancer detection. Proceedings of the National Aca demy of Sciences, 2008, 105, s. 10513–10518. 6 Thomson, J. M. – Newman, M. – Parker, J. S. – Morin-Kensicki, E. M. – Wright, T. – Hammond, S. M.: Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes & Development, 2006, 20, s. 2202–2207. 7 Chang, T.-C. – Yu, D. – Lee, Y.-S. – Wentzel, E. A. – Arking, D. E. – West, K. M. – Dang, C. V. – Thomas-Tikhonenko, A. – Mendell, J. T.: Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, s. 43–50. 8 Johnson, S. M. – Grosshans, H. – Shingara, J. – Byrom, M. – Labourier, E. – Reinert, K. L. – Brown, D. – Slack, F. J.: RAS Is regulated by the let-7 MicroRNA Family. Cell, 2005, 120, s. 635–647. 9 He, L. – He, X. – Lowe, S. W. – Hannon, G. J.: microRNAs join the p53 network – another piece in the tumor-suppression puzzle. Nature Reviews Cancer, 2007, 7, s. 819–822. 10Su, X. – Chakravarti, D. – Cho, M. S. – Liu, L. – Gi, Y. J. – Lin, Y.-L. – Leung, M. L. – El-Naggar, A. – Creighton, C. J. – Suraoka, M. B. – Wistuba, I. – Flores, E. R.: TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature, 2010, 467, s. 986–990. 11Godlewski, J. – Nowicki, M. O. – Bronisz, A. – Nuovo, G. – Palatini, J. – De Lay, M. – Van Brocklyn, J. – Ostrowski, M. C. – Chiocca, E. A. – Lawler, S. E.: MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular Cell, 2010, 37, s. 620–632. 12Anand, S. – Majeti, B. K. – Murphy, L. M. – Mukthavaram, R. – Scheppke, L. – Huang, M. – Shields, D. J. – Lindquist, J. N. – Lapinski, P. E. – King, P. D. – Weis, S. M. – Cheresh, D. A.: MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine, 2010, 16, s. 909–914. ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura